Literature DB >> 2972629

Proliferative and cytolytic potentials of purified human tumor-infiltrating T lymphocytes. Impaired response to mitogen-driven stimulation despite T-cell receptor expression.

S Miescher1, M Stoeck, L Qiao, C Barras, L Barrelet, V von Fliedner.   

Abstract

Using limiting dilution analysis (LDA) we have previously shown that in most instances, the frequency (F) of proliferative T lymphocyte precursors (PTL-P) was strikingly reduced in tumor-infiltrating lymphocytes (TIL). In this study involving 19 cases, we show that the impaired clonogenic potential of CD2+ TILs is primarily caused by an intrinsic defect rather than to suppressor T cells or to a direct effect of the tumor cells usually present in the culture system. This was demonstrated by experiments in which the F of PTL-Ps was quantitated both in highly purified CD2+ TILs (using a cell-sorter) and in non-purified TIL suspensions (still containing tumor cells), which originated from the same biopsy specimen. The F of PTL-Ps was virtually identical in either sorted or nonsorted suspensions and the data from LDA were always consistent with the single-hit Poisson model, indicating that no suppressor cells interfered with growth of CD2+ TIL. Stimulation of sorted CD2+ TIL in low-density cultures by either phytohemagglutinin or anti-CD3-monoclonal antibody (MAb) indicated that the antigen-dependent activation pathway was impaired, although structurally intact T-cell receptor (TCR) complexes were apparently expressed, as assessed by immunofluorescence. The depressed proliferative response of CD2+ TIL could not be reversed in vitro when phorbol-esters were used in combination with ionomycin, which bypass the TCR. Nevertheless, 180 clones obtained from 8 cases were analyzed for their cytolytic activity. The majority mediated specific lytic activity (against unknown antigens), as assessed by lectin-dependent cell cytotoxicity, whereas only 6% of them manifested lymphokine-activated killing on appropriate targets.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2972629     DOI: 10.1002/ijc.2910420504

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  21 in total

1.  Tumour infiltrating lymphocytes: insights into tumour immunology and potential therapeutic implications.

Authors:  K F Yoong; D H Adams
Journal:  Clin Mol Pathol       Date:  1996-10

2.  CD3 hyporesponsiveness and in vitro apoptosis are features of T cells from both malignant and nonmalignant secondary lymphoid organs.

Authors:  S Agrawal; J Marquet; M H Delfau-Larue; C Copie-Bergman; H Jouault; F Reyes; A Bensussan; J P Farcet
Journal:  J Clin Invest       Date:  1998-11-01       Impact factor: 14.808

Review 3.  Immunosuppression in human tumor-host interaction: role of cytokines and alterations in signal-transducing molecules.

Authors:  R Kiessling; K Kono; M Petersson; K Wasserman
Journal:  Springer Semin Immunopathol       Date:  1996

Review 4.  Tumor-infiltrating lymphocytes: their phenotype, functions and clinical use.

Authors:  T L Whiteside; G Parmiani
Journal:  Cancer Immunol Immunother       Date:  1994-07       Impact factor: 6.968

5.  Activation and expansion of tumour-infiltrating lymphocytes by anti-CD3 and anti-CD28 monoclonal antibodies.

Authors:  E W Nijhuis; E vd Wiel-van Kemenade; C G Figdor; R A van Lier
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

6.  Time course of changes in phenotypes of cultured tumor-infiltrating lymphocytes isolated from human colorectal cancer.

Authors:  M Shimazaki; M Ninomiya; Y Muto; K Saito; H Moriwaki
Journal:  Gastroenterol Jpn       Date:  1990-04

7.  Responses to T cell receptor/CD3 and interleukin-2 receptor stimulation are altered in T cells from B cell non-Hodgkin's lymphomas.

Authors:  S Kudoh; Q Wang; O F Hidalgo; P Rayman; R R Tubbs; M G Edinger; V Kolenko; J Panuto; R Bukowski; J H Finke
Journal:  Cancer Immunol Immunother       Date:  1995-09       Impact factor: 6.968

8.  Localization of T cell receptor (TCR)-gamma delta + T cells into human colorectal cancer: flow cytometric analysis of TCR-gamma delta expression in tumour-infiltrating lymphocytes.

Authors:  N Watanabe; A Hizuta; N Tanaka; K Orita
Journal:  Clin Exp Immunol       Date:  1995-10       Impact factor: 4.330

9.  Reduced expression of distinct T-cell CD molecules by collagenase/DNase treatment.

Authors:  W M Mulder; H Koenen; A J van de Muysenberg; E Bloemena; J Wagstaff; R J Scheper
Journal:  Cancer Immunol Immunother       Date:  1994-04       Impact factor: 6.968

10.  In vitro expansion and analysis of T lymphocyte microcultures obtained from the vaccination sites of cancer patients undergoing active specific immunization with autologous Newcastle-disease-virus-modified tumour cells.

Authors:  M Stoeck; C Marland-Noske; M Manasterski; R Zawatzky; S Horn; V Möbus; P Schlag; V Schirrmacher
Journal:  Cancer Immunol Immunother       Date:  1993-09       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.